Clinical Trial Update: Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating MGN1703 as maintenance treatment in metastatic colorectal cancer patients who showed tumor reduction during induction t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MGN1703 (MGN1703)

Snippet

Sponsor: Mologen AG | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: UNKNOWN